Glucagon-like Peptide 1 Receptor Agonist use and the effect on diabetic retinopathy: An uncertain relationship

IF 2.8 4区 医学 Q3 BIOCHEMISTRY & MOLECULAR BIOLOGY Peptides Pub Date : 2024-05-03 DOI:10.1016/j.peptides.2024.171240
Benjamin T.K. Hui , Jian Lee Yeong , Tunde Peto , Colin E. Willoughby
{"title":"Glucagon-like Peptide 1 Receptor Agonist use and the effect on diabetic retinopathy: An uncertain relationship","authors":"Benjamin T.K. Hui ,&nbsp;Jian Lee Yeong ,&nbsp;Tunde Peto ,&nbsp;Colin E. Willoughby","doi":"10.1016/j.peptides.2024.171240","DOIUrl":null,"url":null,"abstract":"<div><p>Glucagon-like Peptide 1 Receptor Agonists (GLP-1 RAs) are a group of relatively novel medications for the treatment of diabetes mellitus. These medications can mimic the naturally occurring incretins of the body, which promote the release of insulin in response to hyperglycaemia. The anti-glycaemic effects of these medications can be profound and carry other metabolic benefits such as promoting weight loss. Clinical trials have shown GLP-1 RAs are safe to use from a cardiovascular perspective. However, some trials have suggested a link between GLP-1 RA use and worsening diabetic retinopathy. The conclusions surrounding this link are poorly established as data is drawn primarily from cardiovascular outcome trials. If an association does exist, a possible explanation might be the observed phenomenon of early worsening diabetic retinopathy with rapid correction of hyperglycaemic states. Trials which look at diabetic retinopathy as a primary outcome in relation to use of GLP-1 RAs are sparse and warrant investigation given the growing use of this group of medications. Therefore currently, it is uncertain what effect, beneficial or adverse, GLP-1 RA use has on diabetic retinopathy. This article provides an overview of GLP-1 RA use as a treatment for diabetes mellitus and the current understanding of their relationship with diabetic retinopathy.</p></div>","PeriodicalId":19765,"journal":{"name":"Peptides","volume":"178 ","pages":"Article 171240"},"PeriodicalIF":2.8000,"publicationDate":"2024-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Peptides","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0196978124000937","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Glucagon-like Peptide 1 Receptor Agonists (GLP-1 RAs) are a group of relatively novel medications for the treatment of diabetes mellitus. These medications can mimic the naturally occurring incretins of the body, which promote the release of insulin in response to hyperglycaemia. The anti-glycaemic effects of these medications can be profound and carry other metabolic benefits such as promoting weight loss. Clinical trials have shown GLP-1 RAs are safe to use from a cardiovascular perspective. However, some trials have suggested a link between GLP-1 RA use and worsening diabetic retinopathy. The conclusions surrounding this link are poorly established as data is drawn primarily from cardiovascular outcome trials. If an association does exist, a possible explanation might be the observed phenomenon of early worsening diabetic retinopathy with rapid correction of hyperglycaemic states. Trials which look at diabetic retinopathy as a primary outcome in relation to use of GLP-1 RAs are sparse and warrant investigation given the growing use of this group of medications. Therefore currently, it is uncertain what effect, beneficial or adverse, GLP-1 RA use has on diabetic retinopathy. This article provides an overview of GLP-1 RA use as a treatment for diabetes mellitus and the current understanding of their relationship with diabetic retinopathy.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
胰高血糖素样肽 1 受体激动剂的使用与糖尿病视网膜病变的影响:不确定的关系
胰高血糖素样肽 1 受体激动剂(GLP-1 RAs)是一组治疗糖尿病的相对新型药物。这些药物可以模拟人体自然产生的胰岛素增量蛋白,从而促进胰岛素的释放,以应对高血糖。这些药物的抗血糖效果非常明显,还能带来其他代谢方面的益处,如促进减肥。临床试验表明,从心血管角度来看,使用 GLP-1 RAs 是安全的。然而,一些试验表明,使用 GLP-1 RA 与糖尿病视网膜病变恶化之间存在联系。由于数据主要来自心血管结果试验,因此围绕这种联系的结论尚不明确。如果确实存在关联,一个可能的解释可能是观察到的糖尿病视网膜病变早期恶化现象与快速纠正高血糖状态有关。将糖尿病视网膜病变作为与使用 GLP-1 RAs 有关的主要结果的试验很少,鉴于这类药物的使用越来越多,值得进行调查。因此,目前还不能确定使用 GLP-1 RA 对糖尿病视网膜病变有什么影响,是有益还是有害。本文概述了 GLP-1 RA 作为糖尿病治疗药物的使用情况,以及目前对其与糖尿病视网膜病变关系的认识。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Peptides
Peptides 医学-生化与分子生物学
CiteScore
6.40
自引率
6.70%
发文量
130
审稿时长
28 days
期刊介绍: Peptides is an international journal presenting original contributions on the biochemistry, physiology and pharmacology of biological active peptides, as well as their functions that relate to gastroenterology, endocrinology, and behavioral effects. Peptides emphasizes all aspects of high profile peptide research in mammals and non-mammalian vertebrates. Special consideration can be given to plants and invertebrates. Submission of articles with clinical relevance is particularly encouraged.
期刊最新文献
The Viktor Mutt Award Lecture 2024 to Thomas Hökfelt. The effects of corticotropin-releasing factor (CRF) and urocortins on the noradrenaline (NA) released from the locus coeruleus (LC). Corrigendum to "Lasso peptides realm: Insights and applications" Peptides 182(December) (2024) 171317. Host defense peptides at the crossroad of endothelial cell physiology: Insight into mechanistic and pharmacological implications Discovery of the bioactive form of glucagon-like peptide-1: An attempt to correct some misconceptions
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1